KRAS Inhibitors — The "Undruggable Target"? A Thing of the Past
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a key member of the RAS family. Mutations in KRAS are among the most common oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. It is estimated that KRAS mutations ...
危险品化学品经营许可证（带存储）